SPRY vs STRO

ARS Pharmaceuticals, Inc. vs Sutro Biopharma, Inc. — Valuation Comparison 2026

SPRY

Biotechnology
ARS Pharmaceuticals, Inc.
Quality
4.7
out of 10
Value Trap
24
SAFE
Price
$9.40
Last close
Models
8/13
Active
VS

STRO

Biotechnology
Sutro Biopharma, Inc.
Quality
5.6
out of 10
Value Trap
24
SAFE
Price
$29.63
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType SPRY Fair ValueSPRY Upside STRO Fair ValueSTRO Upside
Bayesian DCF Intrinsic $2.27 -75.8% $7.89 -73.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.53 -83.7% $7.27 -75.5%
Dynamic NAV Asset-Based $4.73 -84.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for SPRY vs STRO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SPRY vs STRO — Which Stock Is More Undervalued?

STRO scores higher with a 5.6/10 quality rating vs SPRY's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ARS Pharmaceuticals, Inc. (SPRY) and Sutro Biopharma, Inc. (STRO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SPRY currently trades at $9.40 with a QOC of 4.7/10, while STRO trades at $29.63 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).